摘要
目的观察培美曲塞(pemetrexed)联合卡铂(carboplatin)治疗老年晚期非小细胞肺癌的临床疗效及毒副反应。方法老年晚期非小细胞肺癌患者共46例,培美用量75mg/m2,每天静脉滴注,同时配伍卡铂AUC=5mg·ml-1·min-1,每天静脉滴注。21天为1个疗程,每例患者至少接受2个疗程的治疗。结果46例患者均可评价疗效,无完全缓解病例(CR),21例获部分缓解(PR),20例稳定(SD),5例疾病进展(PD),总有效率为45.6%(21/46),其中位疾病进展时间为4.7个月,中位生存时间10.3个月(3～20个月),1年生存率为52.2%。毒性反应主要有骨髓抑制、恶心、呕吐和腹泻以及白细胞下降导致的发热等。但患者多为Ⅰ、Ⅱ度反应,耐受良好。结论培美曲塞联合卡铂是一种对老年晚期非小细胞癌有效的治疗方法,毒性反应轻,临床使用安全。
Objective To evaluate the curative effect and toxic reaction of pemetrexed combination with carboplatin as the therapy in advanced non-small cell lung cancer （NSCLC） of senium. Methods A total of 46 chemotherapy naive patients with stage Ⅲ B or Ⅳ NSCLC were enrolled in this study. Pemetrexed was given at a dose of 75 mg/m^2 over a 1 hour i.v. per day. Carboplatin dosed to an area under the curve （AUC） of 5 mg·ml^-1·min^-1 was administered i.v. quaque die. The chemotherapy was repeated every 21 days. Each patient was given at least 2 cycles. Results The curative effects of all the patients were evaluated. Among the 46 patients, the symptoms of 21 had been partially remissioned, 20 stabilized and 5 progressed. The total effective rate was 45.6% （21/46）. Median time to progression （TTP） was 4. 7 months. Median survival duration was 10. 3 months （3 - 20 months）, and one year survival rate was 52. 2%. The major toxicity included neutropenia, vomiting and diarrhea, impaired liver function, febrile neutropenia, etc. The severity of these side effect was in grade Ⅰ - Ⅱ and well tolerated. Conclusion Pemetrexed combination with carboplatin is effective in the treatment of advanced non-small cell lung cancer, with mild to moderate side effect and safety in clinical practice.
出处
《临床肺科杂志》
2009年第4期492-494,共3页
Journal of Clinical Pulmonary Medicine
关键词
非小细胞肺癌
培美多塞
卡铂
老年
non-small cell lung cancer
pemetrexed
carboplatin
senium
